Canada · Delayed Price · Currency is CAD BioSyent Statistics
Total Valuation
BioSyent has a market cap or net worth of CAD 136.72 million. The enterprise value is 114.22 million.
| Market Cap | 136.72M |
| Enterprise Value | 114.22M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | Nov 28, 2025 |
Share Statistics
BioSyent has 11.26 million shares outstanding. The number of shares has decreased by -2.73% in one year.
| Current Share Class | 11.26M |
| Shares Outstanding | 11.26M |
| Shares Change (YoY) | -2.73% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 13.96% |
| Owned by Institutions (%) | 19.49% |
| Float | 8.60M |
Valuation Ratios
The trailing PE ratio is 16.25 and the forward PE ratio is 14.28.
| PE Ratio | 16.25 |
| Forward PE | 14.28 |
| PS Ratio | 3.24 |
| PB Ratio | 3.43 |
| P/TBV Ratio | 3.89 |
| P/FCF Ratio | 16.87 |
| P/OCF Ratio | 16.80 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.43, with an EV/FCF ratio of 14.09.
| EV / Earnings | 13.23 |
| EV / Sales | 2.71 |
| EV / EBITDA | 9.43 |
| EV / EBIT | 10.02 |
| EV / FCF | 14.09 |
Financial Position
The company has a current ratio of 5.06, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.06 |
| Quick Ratio | 4.18 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.11 |
| Interest Coverage | 219.94 |
Financial Efficiency
Return on equity (ROE) is 22.35% and return on invested capital (ROIC) is 17.99%.
| Return on Equity (ROE) | 22.35% |
| Return on Assets (ROA) | 15.28% |
| Return on Invested Capital (ROIC) | 17.99% |
| Return on Capital Employed (ROCE) | 28.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.90 |
| Inventory Turnover | 1.64 |
Taxes
In the past 12 months, BioSyent has paid 3.17 million in taxes.
| Income Tax | 3.17M |
| Effective Tax Rate | 26.85% |
Stock Price Statistics
The stock price has increased by +6.13% in the last 52 weeks. The beta is 0.39, so BioSyent's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +6.13% |
| 50-Day Moving Average | 11.28 |
| 200-Day Moving Average | 11.31 |
| Relative Strength Index (RSI) | 67.35 |
| Average Volume (20 Days) | 4,905 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSyent had revenue of CAD 42.18 million and earned 8.63 million in profits. Earnings per share was 0.75.
| Revenue | 42.18M |
| Gross Profit | 32.67M |
| Operating Income | 11.40M |
| Pretax Income | 11.80M |
| Net Income | 8.63M |
| EBITDA | 11.98M |
| EBIT | 11.40M |
| Earnings Per Share (EPS) | 0.75 |
Balance Sheet
The company has 23.40 million in cash and 892,878 in debt, giving a net cash position of 22.50 million or 2.00 per share.
| Cash & Cash Equivalents | 23.40M |
| Total Debt | 892,878 |
| Net Cash | 22.50M |
| Net Cash Per Share | 2.00 |
| Equity (Book Value) | 39.90M |
| Book Value Per Share | 3.54 |
| Working Capital | 28.86M |
Cash Flow
In the last 12 months, operating cash flow was 8.14 million and capital expenditures -34,716, giving a free cash flow of 8.10 million.
| Operating Cash Flow | 8.14M |
| Capital Expenditures | -34,716 |
| Free Cash Flow | 8.10M |
| FCF Per Share | 0.72 |
Margins
Gross margin is 77.46%, with operating and profit margins of 27.04% and 20.47%.
| Gross Margin | 77.46% |
| Operating Margin | 27.04% |
| Pretax Margin | 27.98% |
| Profit Margin | 20.47% |
| EBITDA Margin | 28.40% |
| EBIT Margin | 27.04% |
| FCF Margin | 19.22% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 1.65%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 1.65% |
| Dividend Growth (YoY) | 11.11% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 25.50% |
| Buyback Yield | 2.73% |
| Shareholder Yield | 4.37% |
| Earnings Yield | 6.31% |
| FCF Yield | 5.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSyent has an Altman Z-Score of 13.13 and a Piotroski F-Score of 5.
| Altman Z-Score | 13.13 |
| Piotroski F-Score | 5 |